Organoids in Cancer Research and Regenerative Medicine: Current Status, Challenges, and Future Prospects

Abstract

Cancer and tissue regeneration pose great challenges to global health, as cancer treatment is impeded by tumor heterogeneity and therapy resistance, while regenerative medicine is constrained by donor shortages and difficulties in replicating native tissue structures. Organoids, as advanced three-dimensional multicellular structures derived from stem cells, have emerged as transformative tools in biomedical research. They recapitulate key aspects of native human tissue composition and functions, offering enhanced physiological relevance over traditional models. Therefore, this review aims to highlight the latest advancements in organoid technology within the fields of cancer research and regenerative medicine. We begin by discussing the fundamental aspects of organoid generation, characterization, and application. Furthermore, recent progress in both cancer-oriented and regeneration-focused organoids is summarized, with an emphasis on their applications in disease modeling, drug screening, mechanistic analysis, and precision medicine. Based on an extensive review of the literature, the current challenges and future directions in the development and application of organoid models are discussed. As organoid technology continues to evolve, it is anticipated that more high-quality studies will further advance medical science and foster innovation in personalized therapeutics.

Keywords

cancer / disease modeling / drug screening / organoids / regenerative medicine

References

[1] K. L. McKinley, M. T. Longaker, and S. Naik, “Emerging Frontiers in Regenerative Medicine,” Science 380, no. 6647 (2023): 796–798.

[2] A. Jassim, E. P. Rahrmann, B. D. Simons, et al., “Cancers Make Their Own Luck: Theories of Cancer Origins,” Nature Reviews Cancer 23, no. 10 (2023): 710–724.

[3] R. L. Siegel, T. B. Kratzer, A. N. Giaquinto, et al., “Cancer Statistics, 2025,” CA: A Cancer Journal for Clinicians 75, no. 1 (2025): 10–45.

[4] M. Demicco, X. Z. Liu, K. Leithner, et al., “Metabolic Heterogeneity in Cancer,” Nature Metabolism 6, no. 1 (2024): 18–38.

[5] B. L. LeSavage, R. A. Suhar, N. Broguiere, et al., “Next-generation Cancer Organoids,” Nature Materials 21, no. 2 (2022): 143–159.

[6] Z. Zhao, X. Chen, A. Dowbaj, et al., “Organoids,” Nature Reviews Methods Primers 2 (2022): 94.

[7] M. J. Kratochvil, A. J. Seymour, T. L. Li, et al., “Engineered Materials for Organoid Systems,” Nature Reviews Materials 4, no. 9 (2019): 606–622.

[8] X. Y. Tang, S. Wu, D. Wang, et al., “Human Organoids in Basic Research and Clinical Applications,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 168.

[9] D. Tuveson and H. Clevers, “Cancer Modeling Meets human Organoid Technology,” Science 364, no. 6444 (2019): 952–955.

[10] A. Dart, “Organoid 2.0,” Nature Reviews Cancer 19, no. 3 (2019): 126–127.

[11] G. Rossi, A. Manfrin, and M. P. Lutolf, “Progress and Potential in Organoid Research,” Nature Reviews Genetics 19, no. 11 (2018): 671–687.

[12] M. Kim, H. Mun, C. O. Sung, et al., “Patient-derived Lung Cancer Organoids as in Vitro Cancer Models for Therapeutic Screening,” Nature Communications 10, no. 1 (2019): 3991.

[13] J. T. Neal, X. Li, J. Zhu, et al., “Organoid Modeling of the Tumor Immune Microenvironment,” Cell 175, no. 7 (2018): 1972–1988.

[14] J. Wang, D. Zhou, R. Li, et al., “Protocol for Engineering Bone Organoids From Mesenchymal Stem Cells,” Bioactive Materials 45 (2025): 388–400.

[15] M. M. A. Verstegen, R. P. Coppes, A. Beghin, et al., “Clinical Applications of human Organoids,” Nature Medicine 31, no. 2 (2025): 409–421.

[16] M. T. Kozlowski, C. J. Crook, and H. T. Ku, “Towards Organoid Culture Without Matrigel,” Communications Biology 4, no. 1 (2021): 1387.

[17] D. Zhou, Z. Xia, and J. Su, “Organoids: The Future of Disease Modelling and Therapeutics,” Biomaterials Translational 5, no. 4 (2024): 335–336.

[18] H. Clevers, “Modeling Development and Disease With Organoids,” Cell 165, no. 7 (2016): 1586–1597.

[19] K. Kawasaki, K. Toshimitsu, M. Matano, et al., “An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-phenotype Mapping,” Cell 183, no. 5 (2020): 1420–1435.

[20] Y. J. Zhu, L. Y. Sun, X. Y. Wu, et al., “Engineered human Organoids for Biomedical Applications,” Advanced Functional Materials 34, no. 11 (2024): 2310961.

[21] D. Xiang, A. He, R. Zhou, et al., “Building Consensus on the Application of Organoid-based Drug Sensitivity Testing in Cancer Precision Medicine and Drug Development,” Theranostics 14, no. 8 (2024): 3300–3316.

[22] T. Sato, R. G. Vries, H. J. Snippert, et al., “Single Lgr5 Stem Cells Build Crypt-villus Structures in Vitro Without a Mesenchymal Niche,” Nature 459, no. 7244 (2009): 262–265.

[23] M. Eiraku, K. Watanabe, M. Matsuo-Takasaki, et al., “Self-organized Formation of Polarized Cortical Tissues From ESCs and Its Active Manipulation by Extrinsic Signals,” Cell Stem Cell 3, no. 5 (2008): 519–532.

[24] J. Drost and H. Clevers, “Translational Applications of Adult Stem Cell-derived Organoids,” Development (Cambridge, England) 144, no. 6 (2017): 968–975.

[25] D. Bayik and J. D. Lathia, “Cancer Stem Cell-immune Cell Crosstalk in Tumour Progression,” Nature Reviews Cancer 21, no. 8 (2021): 526–536.

[26] Y. Liu, J. Wang, T. C. Südhof, et al., “Efficient Generation of Functional Neurons From Mouse Embryonic Stem Cells via Neurogenin-2 Expression,” Nature Protocols 18, no. 10 (2023): 2954–2974.

[27] A. Sharma, S. Sances, M. J. Workman, et al., “Multi-lineage human iPSC-derived Platforms for Disease Modeling and Drug Discovery,” Cell Stem Cell 26, no. 3 (2020): 309–329.

[28] E. Gabriel, W. Albanna, G. Pasquini, et al., “Human Brain Organoids Assemble Functionally Integrated Bilateral Optic Vesicles,” Cell Stem Cell 28, no. 10 (2021): 1740–1757.

[29] F. Schutgens and H. Clevers, “Human Organoids: Tools for Understanding Biology and Treating Diseases,” Annual Review of Pathology: Mechanisms of Disease 15 (2020): 211–234.

[30] Y. Shao, J. Wang, A. Jin, et al., “Biomaterial-assisted Organoid Technology for Disease Modeling and Drug Screening,” Materials Today Bio 30 (2025): 101438.

[31] S. Kim, S. Min, Y. S. Choi, et al., “Tissue Extracellular Matrix Hydrogels as Alternatives to Matrigel for Culturing Gastrointestinal Organoids,” Nature Communications 13, no. 1 (2022): 1692.

[32] J. S. Kim, C. H. Park, E. Kim, et al., “Establishing 3D Organoid Models From Patient-derived Conditionally Reprogrammed Cells to Bridge Preclinical and Clinical Insights in Pancreatic Cancer,” Molecular Cancer 24, no. 1 (2025): 162.

[33] S. S. Chen, X. Chen, Z. Geng, et al., “The Horizon of Bone Organoid: A Perspective on Construction and Application,” Bioactive Materials 18 (2022): 15–25.

[34] E. A. Aisenbrey and W. L. Murphy, “Synthetic Alternatives to Matrigel,” Nature Reviews Materials 5, no. 7 (2020): 539–551.

[35] G. F. Li, D. Y. Zhou, S. H. Sheng, et al., “Hydrogel for Bone Microenvironment: Strategy and Application,” Chemical Engineering Journal 499 (2024): 156554.

[36] J. W. Kim, S. A. Nam, J. Yi, et al., “Kidney Decellularized Extracellular Matrix Enhanced the Vascularization and Maturation of human Kidney Organoids,” Advanced Science (Weinh) 9, no. 15 (2022): e2103526.

[37] Y. L. Mo, J. Wang, H. J. Yang, et al., “Artificial Intelligence for Organoids Multidimensional Assessment,” Smartmat 6, no. 3 (2025): e70016.

[38] Y. Gu, W. Zhang, X. Wu, et al., “Organoid Assessment Technologies,” Clinical and Translational Medicine 13, no. 12 (2023): e1499.

[39] S. T. Schafer, A. A. Mansour, J. C. M. Schlachetzki, et al., “An in Vivo Neuroimmune Organoid Model to Study human Microglia Phenotypes,” Cell 186, no. 10 (2023): 2111–2126.

[40] M. Li and J. C. Izpisua Belmonte, “Organoids—preclinical Models of human Disease,” New England Journal of Medicine 380, no. 6 (2019): 569–579.

[41] H. C. H. Lau, O. Kranenburg, H. Xiao, et al., “Organoid Models of Gastrointestinal Cancers in Basic and Translational Research,” Nature Reviews Gastroenterology and Hepatology 17, no. 4 (2020): 203–222.

[42] F. Weeber, M. van de Wetering, M. Hoogstraat, et al., “Preserved Genetic Diversity in Organoids Cultured From Biopsies of human Colorectal Cancer Metastases,” Proceedings of the National Academy of Sciences of the United States of America 112, no. 43 (2015): 13308–13311.

[43] S. Mo, P. Tang, W. Luo, et al., “Patient-derived Organoids From Colorectal Cancer With Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy,” Advanced Science (Weinh) 9, no. 31 (2022): e2204097.

[44] X. F. Wan, Z. K. Zhou, and D. Wang, “Organoids as a Platform for Personalized Antisense Oligonucleotide Screening: Advancing Precision Medicine,” Organoid Research 1, no. 3 (2025): 025120012.

[45] C. Calandrini, F. Schutgens, R. Oka, et al., “An Organoid Biobank for Childhood Kidney Cancers That Captures Disease and Tissue Heterogeneity,” Nature Communications 11, no. 1 (2020): 1310.

[46] A. W. J. van Renterghem, J. van de Haar, and E. E. Voest, “Functional Precision Oncology Using Patient-derived Assays: Bridging Genotype and Phenotype,” Nature Reviews Clinical Oncology 20, no. 5 (2023): 305–317.

[47] G. J. Yoshida, “Applications of Patient-derived Tumor Xenograft Models and Tumor Organoids,” Journal of Hematology & Oncology 13, no. 1 (2020): 4.

[48] M. M. Naffaa, “Bridging Molecular Mechanisms and Therapeutic Innovations: The Role of Brain Organoids in Neurodevelopmental Disorder Research,” Organoid Research 1, no.3 (2025): 025100010.

[49] J. Lv, X. Du, M. Wang, et al., “Construction of Tumor Organoids and Their Application to Cancer Research and Therapy,” Theranostics 14, no. 3 (2024): 1101–1125.

[50] Y. Zhang, Q. Hu, Y. Pei, et al., “A Patient-specific Lung Cancer Assembloid Model With Heterogeneous Tumor Microenvironments,” Nature Communications 15, no. 1 (2024): 3382.

[51] J. Roper, T. Tammela, N. M. Cetinbas, et al., “In Vivo Genome Editing and Organoid Transplantation Models of Colorectal Cancer and Metastasis,” Nature Biotechnology 35, no. 6 (2017): 569–576.

[52] S. Bian, M. Repic, Z. Guo, et al., “Genetically Engineered Cerebral Organoids Model Brain Tumor Formation,” Nature Methods 15, no. 8 (2018): 631–639.

[53] F. Weeber, S. N. Ooft, K. K. Dijkstra, et al., “Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery,” Cell Chemical Biology 24, no. 9 (2017): 1092–1100.

[54] P. Mukashyaka, P. Kumar, D. J. Mellert, et al., “High-throughput Deconvolution of 3D Organoid Dynamics at Cellular Resolution for Cancer Pharmacology With Cellos,” Nature Communications 14, no. 1 (2023): 8406.

[55] V. Veninga and E. E. Voest, “Tumor Organoids: Opportunities and Challenges to Guide Precision Medicine,” Cancer Cell 39, no. 9 (2021): 1190–1201.

[56] H. H. N. Yan, A. S. Chan, F. P. Lai, et al., “Organoid Cultures for Cancer Modeling,” Cell Stem Cell 30, no. 7 (2023): 917–937.

[57] A. Marsee, F. J. M. Roos, M. M. A. Verstegen, et al., “Building Consensus on Definition and Nomenclature of Hepatic, Pancreatic, and Biliary Organoids,” Cell Stem Cell 28, no. 5 (2021): 816–832.

[58] K. K. Dijkstra, C. M. Cattaneo, F. Weeber, et al., “Generation of Tumor-reactive T Cells by co-culture of Peripheral Blood Lymphocytes and Tumor Organoids,” Cell 174, no. 6 (2018): 1586–1598.

[59] R. Polak, E. T. Zhang, and C. J. Kuo, “Cancer Organoids 2.0: Modelling the Complexity of the Tumour Immune Microenvironment,” Nature Reviews Cancer 24, no. 8 (2024): 523–539.

[60] C. Swanton, E. Bernard, C. Abbosh, et al., “Embracing Cancer Complexity: Hallmarks of Systemic Disease,” Cell 187, no. 7 (2024): 1589–1616.

[61] R. Yang and Y. Yu, “Patient-derived Organoids in Translational Oncology and Drug Screening,” Cancer Letters 562 (2023): 216180.

[62] J. M. Chan, S. Zaidi, J. R. Love, et al., “Lineage Plasticity in Prostate Cancer Depends on JAK/STAT Inflammatory Signaling,” Science 377, no. 6611 (2022): 1180–1191.

[63] S. H. Lee, W. Hu, J. T. Matulay, et al., “Tumor Evolution and Drug Response in Patient-derived Organoid Models of Bladder Cancer,” Cell 173, no. .2 (2018): 515–528.

[64] H. H. N. Yan, H. C. Siu, S. Law, et al., “A Comprehensive human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening,” Cell Stem Cell 23, no. 6 (2018): 882–897.

[65] H. Yang, J. Cheng, H. Zhuang, et al., “Pharmacogenomic Profiling of Intra-tumor Heterogeneity Using a Large Organoid Biobank of Liver Cancer,” Cancer Cell 42, no. 4 (2024): 535–551.

[66] T. Zhan, N. Rindtorff, J. Betge, et al., “CRISPR/Cas9 for Cancer Research and Therapy,” Seminars in Cancer Biology 55 (2019): 106–119.

[67] G. Vlachogiannis, S. Hedayat, A. Vatsiou, et al., “Patient-derived Organoids Model Treatment Response of Metastatic Gastrointestinal Cancers,” Science 359, no. 6378 (2018): 920–926.

[68] Y. Liu, M. Lankadasari, J. Rosiene, et al., “Modeling Lung Adenocarcinoma Metastases Using Patient-derived Organoids,” Cell Reports Medicine 5, no. 10 (2024): 101777.

[69] K. Li, C. Liu, X. Sui, et al., “An Organoid co-culture Model for Probing Systemic Anti-tumor Immunity in Lung Cancer,” Cell Stem Cell 32, no. 8 (2025): 1218–1234.

[70] R. Shi, N. Radulovich, C. Ng, et al., “Organoid Cultures as Preclinical Models of Non-small Cell Lung Cancer,” Clinical Cancer Research 26, no. 5 (2020): 1162–1174.

[71] T. Ebisudani, J. Hamamoto, K. Togasaki, et al., “Genotype-phenotype Mapping of a Patient-derived Lung Cancer Organoid Biobank Identifies NKX2-1-defined Wnt Dependency in Lung Adenocarcinoma,” Cell Reports 42, no. 3 (2023): 112212.

[72] K. Zhang, J. Xi, H. Zhao, et al., “A Dual-functional Microfluidic Chip for Guiding Personalized Lung Cancer Medicine: Combining egfr Mutation Detection and Organoid-based Drug Response Test,” Lab on a Chip 24, no. 6 (2024): 1762–1774.

[73] T. Fukushima, K. Togasaki, J. Hamamoto, et al., “An Organoid Library Unveils Subtype-specific IGF-1 Dependency via a YAP-AP1 Axis in human Small Cell Lung Cancer,” Nature Cancer 6, no. 5 (2025): 874–891.

[74] Y. M. Choi, H. Lee, M. Ann, et al., “3D bioprinted Vascularized Lung Cancer Organoid Models With Underlying Disease Capable of More Precise Drug Evaluation,” Biofabrication 15, no. 3 (2023): 034104.

[75] Y. Zhao, S. Li, L. Zhu, et al., “Personalized Drug Screening Using Patient-derived Organoid and Its Clinical Relevance in Gastric Cancer,” Cell Reports Medicine 5, no. 7 (2024): 101627.

[76] D. Yang, X. Zhang, Z. Hu, et al., “Organoid-based Single Cell Sequencing Revealed the Lineage Evolution During Docetaxel Treatment in Gastric Cancer,” Cancer Letters 619 (2025): 217617.

[77] K. Nanki, K. Toshimitsu, A. Takano, et al., “Divergent Routes Toward Wnt and R-spondin Niche Independency During human Gastric Carcinogenesis,” Cell 174, no. 4 (2018): 856–869.

[78] K. Karlsson, M. J. Przybilla, E. Kotler, et al., “Deterministic Evolution and Stringent Selection During Preneoplasia,” Nature 618, no. 7964 (2023): 383–393.

[79] S. Tabe, K. Takeuchi, K. Aoshima, et al., “A Pancreatic Cancer Organoid Incorporating Macrophages Reveals the Correlation Between the Diversity of Tumor-associated Macrophages and Cancer Cell Survival,” Biomaterials 314 (2025): 122838.

[80] Z. Zhou, K. Van der Jeught, Y. Li, et al., “A T Cell-engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy,” Advanced Science (Weinh) 10, no. 23 (2023): e2300548.

[81] K. Takeuchi, S. Tabe, K. Takahashi, et al., “Incorporation of human iPSC-derived Stromal Cells Creates a Pancreatic Cancer Organoid With Heterogeneous Cancer-associated Fibroblasts,” Cell Reports 42, no. 11 (2023): 113420.

[82] A. Stigliani, R. Ialchina, J. Yao, et al., “Adaptation to an Acid Microenvironment Promotes Pancreatic Cancer Organoid Growth and Drug Resistance,” Cell Reports 43, no. 7 (2024): 114409.

[83] M. Le Compte, E. C. De La Hoz, S. Peeters, et al., “Single-organoid Analysis Reveals Clinically Relevant Treatment-resistant and Invasive Subclones in Pancreatic Cancer,” NPJ Precision Oncology 7, no. 1 (2023): 128.

[84] T. Seino, S. Kawasaki, M. Shimokawa, et al., “Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence During Disease Progression,” Cell Stem Cell 22, no. 3 (2018): 454–467.

[85] X. Duan, T. Zhang, L. Feng, et al., “A Pancreatic Cancer Organoid Platform Identifies an Inhibitor Specific to Mutant Kras,” Cell Stem Cell 31, no. 1 (2024): 71–88.

[86] Y. Li, S. Tang, H. Wang, et al., “A Pancreatic Cancer Organoid Biobank Links Multi-omics Signatures to Therapeutic Response and Clinical Evaluation of statin Combination Therapy,” Cell Stem Cell 32, no. 9 (2025): 1369–1389.

[87] L. Broutier, G. Mastrogiovanni, M. M. Verstegen, et al., “Human Primary Liver Cancer-derived Organoid Cultures for Disease Modeling and Drug Screening,” Nature Medicine 23, no. 12 (2017): 1424–1435.

[88] G. S. van Tienderen, O. Rosmark, R. Lieshout, et al., “Extracellular Matrix Drives Tumor Organoids Toward Desmoplastic Matrix Deposition and Mesenchymal Transition,” Acta Biomaterialia 158 (2023): 115–131.

[89] Y. Saito, T. Muramatsu, Y. Kanai, et al., “Establishment of Patient-derived Organoids and Drug Screening for Biliary Tract Carcinoma,” Cell Reports 27, no. 4 (2019): 1265–1276.

[90] D. Li, R. Zhang, Y. Le, et al., “Organoid-based Assessment of Metal-organic Framework (MOF) Nanomedicines for Ex Vivo Cancer Therapy,” ACS Applied Materials & Interfaces 16, no. 26 (2024): 33070–33080.

[91] R. Tan, Z. Zhang, P. Ding, et al., “A Growth Factor-reduced Culture System for Colorectal Cancer Organoids,” Cancer Letters 588 (2024): 216737.

[92] S. N. Ooft, F. Weeber, K. K. Dijkstra, et al., “Patient-derived Organoids Can Predict Response to Chemotherapy in Metastatic Colorectal Cancer Patients,” Science Translational Medicine 11, no. 513 (2019): eaay2574.

[93] L. Xiong, Y. Xu, Z. Gao, et al., “A Patient-derived Organoid Model Captures Fetal-Like Plasticity in Colorectal Cancer,” Cell Research 35, no. 9 (2025): 642–655.

[94] H. Yang, X. Xiao, L. Zeng, et al., “Integrating cfDNA Liquid Biopsy and Organoid-based Drug Screening Reveals PI3K Signaling as a Promising Therapeutic Target in Colorectal Cancer,” Journal of Translational Medicine 22, no. 1 (2024): 132.

[95] B. Herpers, B. Eppink, M. I. James, et al., “Functional Patient-derived Organoid Screenings Identify MCLA-158 as a Therapeutic EGFR × LGR5 Bispecific Antibody With Efficacy in Epithelial Tumors,” Nature Cancer 3, no. 4 (2022): 418–436.

[96] Y. Yao, X. Xu, L. Yang, et al., “Patient-derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer,” Cell Stem Cell 26, no. 1 (2020): 17–26.

[97] K. Ganesh, C. Wu, K. P. O'Rourke, et al., “A Rectal Cancer Organoid Platform to Study Individual Responses to Chemoradiation,” Nature Medicine 25, no. 10 (2019): 1607–1614.

[98] H. F. Farin, M. H. Mosa, B. Ndreshkjana, et al., “Colorectal Cancer Organoid-stroma Biobank Allows Subtype-specific Assessment of Individualized Therapy Responses,” Cancer Discovery 13, no. 10 (2023): 2192–2211.

[99] R. Dai, W. Chen, Y. Chen, et al., “3D bioprinting Platform Development for High-throughput Cancer Organoid Models Construction and Drug Evaluation,” Biofabrication 16, no. 3 (2024): 035026.

[100] C. Pauli, B. D. Hopkins, D. Prandi, et al., “Personalized in Vitro and in Vivo Cancer Models to Guide Precision Medicine,” Cancer Discovery 7, no. 5 (2017): 462–477.

[101] Y. Zhao, C. Wang, W. Deng, et al., “Patient-derived Ovarian Cancer Organoid Carries Immune Microenvironment and Blood Vessel Keeping High Response to Cisplatin,” MedComm 5, no. 9 (2024): e697.

[102] W. Senkowski, L. Gall-Mas, M. M. Falco, et al., “A Platform for Efficient Establishment and Drug-response Profiling of High-grade Serous Ovarian Cancer Organoids,” Developmental Cell 58, no. 12 (2023): 1106–1121.

[103] X. Chen, X. Liu, Q. H. Li, et al., “A Patient-derived Organoid-based Study Identified an ASO Targeting SNORD14E for Endometrial Cancer Through Reducing Aberrant FOXM1 Expression and β-catenin Nuclear Accumulation,” Journal of Experimental and Clinical Cancer Research 42, no. 1 (2023): 230.

[104] O. Kopper, C. J. de Witte, K. Lõhmussaar, et al., “An Organoid Platform for Ovarian Cancer Captures Intra- and Interpatient Heterogeneity,” Nature Medicine 25, no. 5 (2019): 838–849.

[105] K. Lõhmussaar, R. Oka, J. E. Valle-Inclan, et al., “Patient-derived Organoids Model Cervical Tissue Dynamics and Viral Oncogenesis in Cervical Cancer,” Cell Stem Cell 28, no. 8 (2021): 1380–1396.

[106] B. Hu, R. Wang, D. Wu, et al., “A Promising New Model: Establishment of Patient-derived Organoid Models Covering HPV-related Cervical Pre-cancerous Lesions and Their Cancers,” Advanced Science (Weinh) 11, no. 12 (2024): e2302340.

[107] S. Y. Kim, T. A. E. de Weert, M. Vermeulen, et al., “Organoid Drug Profiling Identifies Methotrexate as a Therapy for SCCOHT, a Rare Pediatric Cancer,” Science Advances 11, no. 9 (2025): eadq1724.

[108] J. Kong, H. Lee, D. Kim, et al., “Network-based Machine Learning in Colorectal and Bladder Organoid Models Predicts Anti-cancer Drug Efficacy in Patients,” Nature Communications 11, no. 1 (2020): 5485.

[109] M. P. Scholtes, M. Akbarzadeh, A. Galaras, et al., “Integrative Analysis of Patient-derived Tumoroids and Ex Vivo Organoid Modelling of ARID1A Loss in Bladder Cancer Reveals Therapeutic Molecular Targets,” Cancer Letters 614 (2025): 217506.

[110] D. Gao, I. Vela, A. Sboner, et al., “Organoid Cultures Derived From Patients With Advanced Prostate Cancer,” Cell 159, no. 1 (2014): 176–187.

[111] L. Puca, R. Bareja, D. Prandi, et al., “Patient Derived Organoids to Model Rare Prostate Cancer Phenotypes,” Nature Communications 9, no. 1 (2018): 2404.

[112] N. Y. Xu, J. Li, M. L. Wang, et al., “Fabrication of a Coculture Organoid Model in the Biomimetic Matrix of Alginate to Investigate Breast Cancer Progression in a TAMs-leading Immune Microenvironment,” ACS Applied Materials & Interfaces 16, no. 9 (2024): 11275–11288.

[113] M. Starostecka, H. Jeong, P. Hasenfeld, et al., “Structural Variant and Nucleosome Occupancy Dynamics Postchemotherapy in a HER2+ Breast Cancer Organoid Model,” Proceedings of the National Academy of Sciences of the United States of America 122, no. 9 (2025): e2415475122.

[114] N. Sachs, J. de Ligt, O. Kopper, et al., “A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity,” Cell 172, no. 1-2 (2018): 373–386.

[115] K. P. Guillen, M. Fujita, A. J. Butterfield, et al., “A human Breast Cancer-derived Xenograft and Organoid Platform for Drug Discovery and Precision Oncology,” Nature Cancer 3, no. 2 (2022): 232–250.

[116] M. Chadwick, C. Yang, L. Liu, et al., “Rapid Processing and Drug Evaluation in Glioblastoma Patient-derived Organoid Models With 4D Bioprinted Arrays,” Iscience 23, no. 8 (2020): 101365.

[117] F. Jacob, R. D. Salinas, D. Y. Zhang, et al., “A Patient-derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity,” Cell 180, no. 1 (2020): 188–204.

[118] A. Al Shihabi, A. Davarifar, H. T. L. Nguyen, et al., “Personalized Chordoma Organoids for Drug Discovery Studies,” Science Advances 8, no. 7 (2022): eabl3674.

[119] L. E. L. Hendriks, J. Remon, C. Faivre-Finn, et al., “Non-small-cell Lung Cancer,” Nature Reviews Disease Primers 10, no. 1 (2024): 71.

[120] R. L. Siegel, K. D. Miller, N. S. Wagle, et al., “Cancer Statistics, 2023,” CA: A Cancer Journal for Clinicians 73, no. 1 (2023): 17–48.

[121] R. Sundar, I. Nakayama, S. R. Markar, et al., “Gastric Cancer,” Lancet 405, no. 10494 (2025): 2087–2102.

[122] T. F. Stoop, A. A. Javed, A. Oba, et al., “Pancreatic Cancer,” Lancet 405, no. 10485 (2025): 1182–1202.

[123] J. E. Maeng and J. L. Ku, “In-depth Organoid Profiling of Pancreatic Cancer,” Nature Reviews Cancer 24, no. 9 (2024): 596.

[124] H. Tiriac, P. Belleau, D. D. Engle, et al., “Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer,” Cancer Discovery 8, no. 9 (2018): 1112–1129.

[125] S. F. Boj, C. I. Hwang, L. A. Baker, et al., “Organoid Models of human and Mouse Ductal Pancreatic Cancer,” Cell 160, no. 1-2 (2015): 324–338.

[126] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.

[127] D. Shek, D. Chen, S. A. Read, et al., “Examining the Gut-liver Axis in Liver Cancer Using Organoid Models,” Cancer Letters 510 (2021): 48–58.

[128] Z. Wang, Y. Guo, Y. Jin, et al., “Establishment and Drug Screening of Patient-derived Extrahepatic Biliary Tract Carcinoma Organoids,” Cancer Cell International 21, no. 1 (2021): 519.

[129] G. S. van Tienderen, L. Li, L. Broutier, et al., “Hepatobiliary Tumor Organoids for Personalized Medicine: A Multicenter View on Establishment, Limitations, and Future Directions,” Cancer Cell 40, no. 3 (2022): 226–230.

[130] M. Schmitt and F. R. Greten, “The Inflammatory Pathogenesis of Colorectal Cancer,” Nature Reviews Immunology 21, no. 10 (2021): 653–667.

[131] M. Díaz-Gay, W. Dos Santos, and S. Moody, “Geographic and Age Variations in Mutational Processes in Colorectal Cancer,” Nature 643, no. 8070 (2025): 230–240.

[132] C. Eng, T. Yoshino, E. Ruíz-García, et al., “Colorectal Cancer,” Lancet 404, no. 10449 (2024): 294–310.

[133] A. C. F. Bolhaqueiro, B. Ponsioen, B. Bakker, et al., “Ongoing Chromosomal Instability and Karyotype Evolution in human Colorectal Cancer Organoids,” Nature Genetics 51, no. 5 (2019): 824–834.

[134] H. Takeda, S. Kataoka, M. Nakayama, et al., “CRISPR-Cas9-mediated Gene Knockout in Intestinal Tumor Organoids Provides Functional Validation for Colorectal Cancer Driver Genes,” Proceedings of the National Academy of Sciences of the United States of America 116, no. 31 (2019): 15635–15644.

[135] M. Fujii, M. Shimokawa, S. Date, et al., “A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements During Tumorigenesis,” Cell Stem Cell 18, no. 6 (2016): 827–838.

[136] E. Strating, M. P. Verhagen, E. Wensink, et al., “Co-cultures of Colon Cancer Cells and Cancer-associated Fibroblasts Recapitulate the Aggressive Features of Mesenchymal-Like Colon Cancer,” Frontiers in Immunology 14 (2023): 1053920.

[137] Q. Sui, X. Zhang, C. Chen, et al., “Inflammation Promotes Resistance to Immune Checkpoint Inhibitors in High Microsatellite Instability Colorectal Cancer,” Nature Communications 13, no. 1 (2022): 7316.

[138] L. Varinelli, M. Guaglio, S. Brich, et al., “Decellularized Extracellular Matrix as Scaffold for Cancer Organoid Cultures of Colorectal Peritoneal Metastases,” Journal of Molecular Cell Biology 14, no. 11 (2023): mjac064.

[139] K. Nakano, E. Oki, M. Yamazaki, et al., “Colorectal Cancer Cell Line-derived Organoid Model With Stem Cell Properties Captures the Regrowing state of Residual Cancer Cells After Neoadjuvant Chemotherapy,” Cell Death Discovery 11, no. 1 (2025): 282.

[140] A. Esposito, A. Agostini, G. Quero, et al., “Colorectal Cancer Patients-derived Immunity-organoid Platform Unveils Cancer-specific Tissue Markers Associated With Immunotherapy Resistance,” Cell Death and Disease 15, no. 12 (2024): 878.

[141] M. van de Wetering, H. E. Francies, J. M. Francis, et al., “Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients,” Cell 161, no. 4 (2015): 933–945.

[142] N. Li, Q. Zhu, Y. Tian, et al., “Mapping and Modeling human Colorectal Carcinoma Interactions With the Tumor Microenvironment,” Nature Communications 14, no. 1 (2023): 7915.

[143] Y. Li, M. Qin, N. Liu, et al., “Organoid Development and Applications in Gynecological Cancers: The New Stage of Tumor Treatment,” Journal of Nanobiotechnology 23, no. 1 (2025): 20.

[144] H. J. Gray, P. Chatterjee, R. Rosati, et al., “Extraordinary Clinical Response to ibrutinib in Low-grade Ovarian Cancer Guided by Organoid Drug Testing,” NPJ Precision Oncology 7, no. 1 (2023): 45.

[145] A. Lopez-Beltran, M. S. Cookson, B. J. Guercio, et al., “Advances in Diagnosis and Treatment of Bladder Cancer,” Bmj 384 (2024): e076743.

[146] L. Dyrskjøt, D. E. Hansel, J. A. Efstathiou, et al., “Bladder Cancer,” Nature Reviews Disease Primers 9, no. 1 (2023): 58.

[147] R. Yang, S. Wang, Z. Li, et al., “Patient-derived Organoid co-culture Systems as next-generation Models for Bladder Cancer Stem Cell Research,” Cancer Letters 625 (2025): 217793.

[148] X. Li, Z. Han, and J. Ai, “Synergistic Targeting Strategies for Prostate Cancer,” Nature Reviews Urology 22, no. 10 (2025): 645–671.

[149] J. Drost, W. R. Karthaus, D. Gao, et al., “Organoid Culture Systems for Prostate Epithelial and Cancer Tissue,” Nature Protocols 11, no. 2 (2016): 347–358.

[150] W. R. Karthaus, P. J. Iaquinta, J. Drost, et al., “Identification of Multipotent Luminal Progenitor Cells in human Prostate Organoid Cultures,” Cell 159, no. 1 (2014): 163–175.

[151] X. Xiong, L. W. Zheng, Y. Ding, et al., “Breast Cancer: Pathogenesis and Treatments,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 49.

[152] A. Bhattacharya, K. Alam, N. S. Roy, et al., “Exploring the Interaction Between Extracellular Matrix Components in a 3D Organoid Disease Model to Replicate the Pathophysiology of Breast Cancer,” Journal of Experimental and Clinical Cancer Research 42, no. 1 (2023): 343.

[153] S. J. Bagley, S. Kothari, R. Rahman, et al., “Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement,” Clinical Cancer Research 28, no. 4 (2022): 594–602.

[154] C. G. Hubert, M. Rivera, L. C. Spangler, et al., “A Three-dimensional Organoid Culture System Derived From human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found in Vivo,” Cancer Research 76, no. 8 (2016): 2465–2477.

[155] M. A. Lancaster and J. A. Knoblich, “Organogenesis in a Dish: Modeling Development and Disease Using Organoid Technologies,” Science 345, no. 6194 (2014): 1247125.

[156] Y. Sasai, “Cytosystems Dynamics in Self-organization of Tissue Architecture,” Nature 493, no. 7432 (2013): 318–326.

[157] C. E. Murry and G. Keller, “Differentiation of Embryonic Stem Cells to Clinically Relevant Populations: Lessons From Embryonic Development,” Cell 132, no. 4 (2008): 661–680.

[158] C. Zhang, Y. Y. Jing, J. H. Wang, et al., “Skeletal Organoids,” Biomaterials Translational 5, no. 4 (2024): 390–410.

[159] M. Pinelli, S. Makdissi, M. Scur, et al., “Peroxisomal Cholesterol Metabolism Regulates Yap-signaling, Which Maintains Intestinal Epithelial Barrier Function and Is Altered in Crohn's disease,” Cell Death and Disease 15, no. 7 (2024): 536.

[160] C. Tindle, A. G. Fonseca, S. Taheri, et al., “A Living Organoid Biobank of Patients With Crohn's disease Reveals Molecular Subtypes for Personalized Therapeutics,” Cell Reports Medicine 5, no. 10 (2024): 101748.

[161] K. Nanki, M. Fujii, M. Shimokawa, et al., “Somatic Inflammatory Gene Mutations in human Ulcerative Colitis Epithelium,” Nature 577, no. 7789 (2020): 254–259.

[162] T. W. Dennison, R. D. Edgar, F. Payne, et al., “Patient-derived Organoid Biobank Identifies Epigenetic Dysregulation of Intestinal Epithelial MHC-I as a Novel Mechanism in Severe Crohn's Disease,” Gut 73, no. 9 (2024): 1464–1477.

[163] T. Tao, P. Deng, Y. Wang, et al., “Microengineered Multi-organoid System From hiPSCs to Recapitulate human Liver-islet Axis in Normal and Type 2 Diabetes,” Advanced Science (Weinh) 9, no. 5 (2022): e2103495.

[164] S. Salas-Silva, Y. Kim, T. H. Kim, et al., “Human Chemically-derived Hepatic Progenitors (hCdHs) as a Source of Liver Organoid Generation: Application in Regenerative Medicine, Disease Modeling, and Toxicology Testing,” Biomaterials 303 (2023): 122360.

[165] Y. Guan, A. Enejder, M. Wang, et al., “A human Multi-lineage Hepatic Organoid Model for Liver Fibrosis,” Nature Communications 12, no. 1 (2021): 6138.

[166] M. Rizwan, C. Ling, C. Guo, et al., “Viscoelastic Notch Signaling Hydrogel Induces Liver Bile Duct Organoid Growth and Morphogenesis,” Advanced Healthcare Materials 11, no. 23 (2022): e2200880.

[167] Y. Liu, A. E. Gilchrist, P. K. Johansson, et al., “Engineered Hydrogels for Organoid Models of human Nonalcoholic Fatty Liver Disease,” Advanced Science (Weinh) 12, no. 22 (2025): e17332.

[168] S. J. Mun, J. S. Ryu, M. O. Lee, et al., “Generation of Expandable human Pluripotent Stem Cell-derived Hepatocyte-Like Liver Organoids,” Journal of Hepatology 71, no. 5 (2019): 970–985.

[169] C. J. Zhang, S. R. Meyer, M. J. O'Meara, et al., “A human Liver Organoid Screening Platform for DILI Risk Prediction,” Journal of Hepatology 78, no. 5 (2023): 998–1006.

[170] E. Carolina, Y. Kuse, A. Okumura, et al., “Generation of human iPSC-derived 3D Bile Duct Within Liver Organoid by Incorporating human iPSC-derived Blood Vessel,” Nature Communications 15, no. 1 (2024): 7424.

[171] K. Peng, W. Xie, T. Wang, et al., “HIF-1α Promotes Kidney Organoid Vascularization and Applications in Disease Modeling,” Stem Cell Research & Therapy 14, no. 1 (2023): 336.

[172] T. J. Borges, Y. Ganchiku, J. O. Aceves, et al., “Exploring Immune Response Toward Transplanted human Kidney Tissues Assembled From Organoid Building Blocks,” Iscience 27, no. 10 (2024): 110957.

[173] M. Koning, S. J. Dumas, E. Meta, et al., “Single Cell Transcriptomics of human Kidney Organoid Endothelium Reveals Vessel Growth Processes and Arterial Maturation Upon Transplantation,” NPJ Regenerative Medicine 10, no. 1 (2025): 32.

[174] G. Wang, H. Wu, X. Zhai, et al., “Kidney Organoid Modeling of WT1 Mutations Reveals Key Regulatory Paths Underlying Podocyte Development,” Advanced Science (Weinh) 11, no. 29 (2024): e2308556.

[175] S. Clerkin, K. Singh, J. L. Davis, et al., “Tuneable Gelatin Methacryloyl (GelMA) Hydrogels for the Directed Specification of Renal Cell Types for hiPSC-derived Kidney Organoid Maturation,” Biomaterials 322 (2025): 123349.

[176] B. Huang, Z. Zeng, S. Kim, et al., “Long-term Expandable Mouse and human-induced Nephron Progenitor Cells Enable Kidney Organoid Maturation and Modeling of Plasticity and Disease,” Cell Stem Cell 31, no. 6 (2024): 921–939.

[177] I. R. Suhito, J. W. Kim, K. M. Koo, et al., “In Situ Detection of Kidney Organoid Generation From Stem Cells Using a Simple Electrochemical Method,” Advanced Science (Weinh) 9, no. 20 (2022): e2200074.

[178] E. Garreta, D. Moya-Rull, A. Marco, et al., “Natural Hydrogels Support Kidney Organoid Generation and Promote in Vitro Angiogenesis,” Advanced Materials 36, no. 34 (2024): e2400306.

[179] H. Lim, D. Kim, H. Yoon, et al., “Developmental Hypoxia Enhances Kidney Organoid Complexity and Maturity,” Advanced Science (Weinh) (2025): e01661.

[180] J. Lee, C. C. Rabbani, H. Gao, et al., “Hair-bearing human Skin Generated Entirely From Pluripotent Stem Cells,” Nature 582, no. 7812 (2020): 399–404.

[181] T. Zhang, S. Sheng, W. Cai, et al., “3-D Bioprinted human-derived Skin Organoids Accelerate Full-thickness Skin Defects Repair,” Bioactive Materials 42 (2024): 257–269.

[182] M. Zhu, H. Zhang, Q. Zhou, et al., “Dynamic GelMA/DNA Dual-network Hydrogels Promote Woven Bone Organoid Formation and Enhance Bone Regeneration,” Advanced Materials 37, no. 24 (2025): e2501254.

[183] G. N. Hall, L. F. Mendes, C. Gklava, et al., “Developmentally Engineered Callus Organoid Bioassemblies Exhibit Predictive in Vivo Long Bone Healing,” Advanced Science (Weinh) 7, no. 2 (2020): 1902295.

[184] Y. Park, E. Cheong, J. G. Kwak, et al., “Trabecular Bone Organoid Model for Studying the Regulation of Localized Bone Remodeling,” Science Advances 7, no. 4 (2021): eabd6495.

[185] J. Wang, Y. Wu, G. F. Li, et al., “Engineering Large-scale Self-mineralizing Bone Organoids With Bone Matrix-inspired Hydroxyapatite Hybrid Bioinks,” Advanced Materials 36, no. 30 (2024): e2309875.

[186] S. Sabate-Soler, S. L. Nickels, C. Saraiva, et al., “Microglia Integration Into human Midbrain Organoids Leads to Increased Neuronal Maturation and Functionality,” Glia 70, no. 7 (2022): 1267–1288.

[187] M. S. Kim, E. A. Ra, S. H. Kweon, et al., “Advanced human iPSC-based Preclinical Model for Parkinson's Disease With Optogenetic Alpha-synuclein Aggregation,” Cell Stem Cell 30, no. 7 (2023): 973–986.

[188] L. M. Smits, L. Reinhardt, P. Reinhardt, et al., “Modeling Parkinson's Disease in Midbrain-Like Organoids,” NPJ Parkinsons Disease 5 (2019): 5.

[189] N. Zhao, C. J. Zhang, X. Zhang, et al., “Transplantation of Derivative Retinal Organoids From Chemically Induced Pluripotent Stem Cells Restored Visual Function,” NPJ Regenerative Medicine 9, no. 1 (2024): 42.

[190] S. Lee, W. G. Chung, H. Jeong, et al., “Electrophysiological Analysis of Retinal Organoid Development Using 3D Microelectrodes of Liquid Metals,” Advanced Materials 36, no. 35 (2024): e2404428.

[191] J. Harkin, K. H. Peña, C. Gomes, et al., “A Highly Reproducible and Efficient Method for Retinal Organoid Differentiation From human Pluripotent Stem Cells,” Proceedings of the National Academy of Sciences of the United States of America 121, no. 25 (2024): e2317285121.

[192] R. Balasubramanian, X. Min, P. M. J. Quinn, et al., “Phase Transition Specified by a Binary Code Patterns the Vertebrate Eye Cup,” Science Advances 7, no. 46 (2021): eabj9846.

[193] C. S. Cowan, M. Renner, M. De Gennaro, et al., “Cell Types of the human Retina and Its Organoids at Single-cell Resolution,” Cell 182, no. 6 (2020): 1623–1640.

[194] A. Saha, E. Capowski, M. A. Fernandez Zepeda, et al., “Cone Photoreceptors in human Stem Cell-derived Retinal Organoids Demonstrate Intrinsic Light Responses That Mimic Those of Primate Fovea,” Cell Stem Cell 29, no. 3 (2022): 460–471.

[195] Y. Hirami, M. Mandai, S. Sugita, et al., “Safety and Stable Survival of Stem-cell-derived Retinal Organoid for 2 Years in Patients With Retinitis Pigmentosa,” Cell Stem Cell 30, no. 12 (2023): 1585–1596.

[196] K. Abe, A. Yamashita, M. Morioka, et al., “Engraftment of Allogeneic iPS Cell-derived Cartilage Organoid in a Primate Model of Articular Cartilage Defect,” Nature Communications 14, no. 1 (2023): 804.

[197] C. Y. Shen, J. Wang, G. F. Li, et al., “Boosting Cartilage Repair With Silk Fibroin-DNA Hydrogel-based Cartilage Organoid Precursor,” Bioactive Materials 35 (2024): 429–444.

[198] C. Y. Shen, Q. R. Zhou, X. Wu, et al., “Accelerating Cartilage Regeneration With DNA-SF Hydrogel Sustained Release System-based Cartilage Organoids,” Military Medical Research 12, no. 1 (2025): 39.

[199] G. Schwank, B. K. Koo, V. Sasselli, et al., “Functional Repair of CFTR by CRISPR/Cas9 in Intestinal Stem Cell Organoids of Cystic Fibrosis Patients,” Cell Stem Cell 13, no. 6 (2013): 653–658.

[200] G. Berkers, P. van Mourik, A. M. Vonk, et al., “Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis,” Cell Reports 26, no. 7 (2019): 1701–1708.

[201] N. Sachs, A. Papaspyropoulos, D. D. Zomer-van Ommen, et al., “Long-term Expanding human Airway Organoids for Disease Modeling,” EMBO Journal 38, no. 4 (2019): e100300.

[202] M. Huch, H. Gehart, R. van Boxtel, et al., “Long-term Culture of Genome-stable Bipotent Stem Cells From Adult human Liver,” Cell 160, no. 1-2 (2015): 299–312.

[203] G. Gómez-Mariano, N. Matamala, S. Martínez, et al., “Liver Organoids Reproduce Alpha-1 Antitrypsin Deficiency-related Liver Disease,” Hepatology International 14, no. 1 (2020):127–137.

[204] I. F. Schene, I. P. Joore, R. Oka, et al., “Prime Editing for Functional Repair in Patient-derived Disease Models,” Nature Communications 11, no. 1 (2020): 5352.

[205] V. Lehmann, I. F. Schene, A. I. Ardisasmita, et al., “The Potential and Limitations of Intrahepatic Cholangiocyte Organoids to Study Inborn Errors of Metabolism,” Journal of Inherited Metabolic Disease 45, no. 2 (2022): 353–365.

[206] Y. Xu, C. Kuppe, J. Perales-Patón, et al., “Adult human Kidney Organoids Originate From CD24⁺ Cells and Represent an Advanced Model for Adult Polycystic Kidney Disease,” Nature Genetics 54, no. 11 (2022): 1690–1701.

[207] T. Tran, C. J. Song, T. Nguyen, et al., “A Scalable Organoid Model of human Autosomal Dominant Polycystic Kidney Disease for Disease Mechanism and Drug Discovery,” Cell Stem Cell 29, no. 7 (2022): 1083–1101.

[208] M. Liu, C. Zhang, X. Gong, et al., “Kidney Organoid Models Reveal Cilium-autophagy Metabolic Axis as a Therapeutic Target for PKD both in Vitro and in Vivo,” Cell Stem Cell 31, no. 1 (2024): 52–70.

[209] A. J. Montano-Loza, M. L. Rodríguez-Perálvarez, G. P. Pageaux, et al., “Liver Transplantation Immunology: Immunosuppression, Rejection, and Immunomodulation,” Journal of Hepatology 78, no. 6 (2023): 1199–1215.

[210] M. R. Lucey, K. N. Furuya, and D. P. Foley, “Liver Transplantation,” New England Journal of Medicine 389, no. 20 (2023): 1888–1900.

[211] W. Kim, Y. Gwon, S. Park, et al., “Therapeutic Strategies of Three-dimensional Stem Cell Spheroids and Organoids for Tissue Repair and Regeneration,” Bioactive Materials 19 (2023):50–74.

[212] B. Yu, D. Zhou, F. Wang, et al., “Organoids for Tissue Repair and Regeneration,” Materials Today Bio 33 (2025): 102013.

[213] M. Dolinger, J. Torres, and S. Vermeire, “Crohn's Disease,” Lancet 403, no. 10432 (2024): 1177–1191.

[214] GBD 2017 inflammatory bowel disease collaborators, “The Global, Regional, and National Burden of Inflammatory Bowel Disease in 195 Countries and territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017,” Lancet Gastroenterology & Hepatology 5, no. 1 (2020): 17–30.

[215] C. T. Stankey, C. Bourges, L. M. Haag, et al., “A Disease-associated Gene Desert Directs Macrophage Inflammation Through ETS2,” Nature 630, no. 8016 (2024): 447–456.

[216] L. Yang, X. Wang, X. Zhou, et al., “A Tunable human Intestinal Organoid System Achieves Controlled Balance Between Self-renewal and Differentiation,” Nature Communications 16, no. 1 (2025): 315.

[217] E. d'Aldebert, M. Quaranta, and M. Sébert, “Characterization of human Colon Organoids From Inflammatory Bowel Disease Patients,” Frontiers in Cell and Developmental Biology 8 (2020): 363.

[218] L. F. Buttó, A. Pelletier, S. K. More, et al., “Intestinal Stem Cell Niche Defects Result in Impaired 3D Organoid Formation in Mouse Models of Crohn's Disease-Like Ileitis,” Stem Cell Reports 15, no. 2 (2020): 389–407.

[219] Y. Kuse and H. Taniguchi, “Present and Future Perspectives of Using human-induced Pluripotent Stem Cells and Organoid Against Liver Failure,” Cell Transplantation 28, no. 1_suppl (2019): 160s–165s.

[220] M. B. Afonso, V. Marques, S. W. C. van Mil, et al., “Human Liver Organoids: From Generation to Applications,” Hepatology 79, no. 6 (2024): 1432–1451.

[221] H. A. Reza, R. Okabe, and T. Takebe, “Organoid Transplant Approaches for the Liver,” Transplant International 34, no. 11 (2021): 2031–2045.

[222] S. A. Schneemann, S. N. Boers, J. J. M. van Delden, et al., “Ethical Challenges for Pediatric Liver Organoid Transplantation,” Science Translational Medicine 12, no. 552 (2020): eaau8471.

[223] T. Tsuchida, S. Murata, S. Hasegawa, et al., “Investigation of Clinical Safety of human ips Cell-derived Liver Organoid Transplantation to Infantile Patients in porcine Model,” Cell Transplantation 29 (2020): 963689720964384.

[224] S. Osonoi and T. Takebe, “Organoid-guided Precision Hepatology for Metabolic Liver Disease,” Journal of Hepatology 80, no. 5 (2024): 805–821.

[225] S. K. Kim, Y. H. Kim, S. Park, et al., “Organoid Engineering With Microfluidics and Biomaterials for Liver, Lung Disease, and Cancer Modeling,” Acta Biomaterialia 132 (2021): 37–51.

[226] T. Takebe, K. Sekine, M. Enomura, et al., “Vascularized and Functional human Liver From an iPSC-derived Organ Bud Transplant,” Nature 499, no. 7459 (2013): 481–484.

[227] T. Takebe, R. R. Zhang, H. Koike, et al., “Generation of a Vascularized and Functional human Liver From an iPSC-derived Organ Bud Transplant,” Nature Protocols 9, no. 2 (2014): 396–409.

[228] A. Hess, S. D. Gentile, A. B. Saad, et al., “Single-cell Transcriptomics Stratifies Organoid Models of Metabolic Dysfunction-associated Steatotic Liver Disease,” EMBO Journal 42, no. 24 (2023): e113898.

[229] S. Kim, N. Jeong, J. Park, et al., “Establishment and Characterization of Mouse Metabolic Dysfunction-associated Steatohepatitis-related Hepatocellular Carcinoma Organoids,” Scientific Reports 14, no. 1 (2024): 27460.

[230] O. Foresto-Neto, L. Menezes-Silva, J. A. Leite, et al., “Immunology of Kidney Disease,” Annual Review of Immunology 42, no. 1 (2024): 207–233.

[231] E. A. J. Hoste, J. A. Kellum, N. M. Selby, et al., “Global Epidemiology and Outcomes of Acute Kidney Injury,” Nature Reviews Nephrology 14, no. 10 (2018): 607–625.

[232] C. Ronco, R. Bellomo, and J. A. Kellum, “Acute Kidney Injury,” Lancet 394, no. 10212 (2019): 1949–1964.

[233] J. A. Kellum, P. Romagnani, G. Ashuntantang, et al., “Acute Kidney Injury,” Nature Reviews Disease Primers 7, no. 1 (2021): 52.

[234] G. B. D. chronic kidney disease collaboration, “Global, Regional, and National Burden of Chronic Kidney Disease, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017,” Lancet 395, no. 10225 (2020): 709–733.

[235] P. Romagnani, R. Agarwal, J. C. N. Chan, et al., “Chronic Kidney Disease,” Nature Reviews Disease Primers 11, no. 1 (2025): 8.

[236] K. Kalantar-Zadeh, T. H. Jafar, D. Nitsch, et al., “Chronic Kidney Disease,” Lancet 398, no. 10302 (2021): 786–802.

[237] A. Przepiorski, A. E. Crunk, E. B. Espiritu, et al., “The Utility of human Kidney Organoids in Modeling Kidney Disease,” Seminars in Nephrology 40, no. 2 (2020): 188–198.

[238] M. Liu, A. Cardilla, J. Ngeow, et al., “Studying Kidney Diseases Using Organoid Models,” Frontiers in Cell and Developmental Biology 10 (2022): 845401.

[239] S. Cui, Y. J. Shin, X. Fang, et al., “CRISPR/Cas9-mediated A4GALT Suppression Rescues Fabry Disease Phenotypes in a Kidney Organoid Model,” Translational Research 258 (2023): 35–46.

[240] S. Cui, X. Fang, H. Lee, et al., “Modeling of Fabry Disease Nephropathy Using Patient Derived human Induced Pluripotent Stem Cells and Kidney Organoid System,” Journal of Translational Medicine 21, no. 1 (2023): 138.

[241] A. I. Astashkina, B. K. Mann, G. D. Prestwich, et al., “A 3-D Organoid Kidney Culture Model Engineered for High-throughput Nephrotoxicity Assays,” Biomaterials 33, no. 18 (2012): 4700–4711.

[242] M. Takasato, P. X. Er, H. S. Chiu, et al., “Kidney Organoids From human iPS Cells Contain Multiple Lineages and Model human Nephrogenesis,” Nature 526, no. 7574 (2015): 564–568.

[243] H. Wu, K. Uchimura, E. L. Donnelly, et al., “Comparative Analysis and Refinement of human PSC-derived Kidney Organoid Differentiation With Single-cell Transcriptomics,” Cell Stem Cell 23, no. 6 (2018): 869–881.

[244] N. A. Hukriede, D. E. Soranno, V. Sander, et al., “Experimental Models of Acute Kidney Injury for Translational Research,” Nature Reviews Nephrology 18, no. 5 (2022): 277–293.

[245] S. M. Czerniecki, N. M. Cruz, J. L. Harder, et al., “High-throughput Screening Enhances Kidney Organoid Differentiation From human Pluripotent Stem Cells and Enables Automated Multidimensional Phenotyping,” Cell Stem Cell 22, no. 6 (2018): 924.

[246] L. J. Hale, S. E. Howden, B. Phipson, et al., “3D organoid-derived human Glomeruli for Personalised Podocyte Disease Modelling and Drug Screening,” Nature Communications 9, no. 1 (2018): 5167.

[247] O. A. Peña and P. Martin, “Cellular and Molecular Mechanisms of Skin Wound Healing,” Nature Reviews Molecular Cell Biology 25, no. 8 (2024): 599–616.

[248] H. E. Talbott, S. Mascharak, M. Griffin, et al., “Wound Healing, Fibroblast Heterogeneity, and Fibrosis,” Cell Stem Cell 29, no. 8 (2022): 1161–1180.

[249] Z. J. Wang, X. Liang, G. Y. Wang, et al., “Emerging Bioprinting for Wound Healing,” Advanced Materials (2023): e2304738.

[250] Z. X. Hong, S. T. Zhu, H. Li, et al., “Bioengineered Skin Organoids: From Development to Applications,” Military Medical Research 10, no. 1 (2023): 40.

[251] J. Lee, W. H. van der Valk, and S. A. Serdy, “Generation and Characterization of Hair-bearing Skin Organoids From human Pluripotent Stem Cells,” Nature Protocols 17, no. 5 (2022): 1266–1305.

[252] J. Lee, R. Böscke, P. C. Tang, et al., “Hair Follicle Development in Mouse Pluripotent Stem Cell-derived Skin Organoids,” Cell Reports 22, no. 1 (2018): 242–254.

[253] R. Li, J. Wang, Q. Lin, et al., “Mechano-responsive Biomaterials for Bone Organoid Construction,” Advanced Healthcare Materials 14, no. 6 (2024): e2404345.

[254] A. Akiva, J. Melke, S. Ansari, et al., “An Organoid for Woven Bone,” Advanced Functional Materials 31, no. 17 (2021): e2010524.

[255] A. Deng, H. Zhang, Y. Hu, et al., “Microsphere Strategy to Generate Conformal Bone Organoid Units With Osteoimmunomodulation and Sustainable Oxygen Supply for Bone Regeneration,” Advanced Science (Weinh) (2025): e01437.

[256] G. N. Hall, W. L. Tam, K. S. Andrikopoulos, et al., “Patterned, Organoid-based Cartilaginous Implants Exhibit Zone Specific Functionality Forming Osteochondral-Like Tissues in Vivo,” Biomaterials 273 (2021): 120820.

[257] T. Gai, H. Zhang, Y. Hu, et al., “Sequential Construction of Vascularized and Mineralized Bone Organoids Using Engineered ECM-DNA-CPO-based Bionic Matrix for Efficient Bone Regeneration,” Bioactive Materials 49 (2025): 362–377.

[258] A. Iordachescu, E. A. B. Hughes, S. Joseph, et al., “Trabecular Bone Organoids: A Micron-scale ‘Humanised’ prototype Designed to Study the Effects of Microgravity and Degeneration,” Nature Partner Journals Microgravity 7, no. 1 (2021): 17.

[259] A. O. Khan, A. Rodriguez-Romera, J. S. Reyat, et al., “Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies,” Cancer Discovery 13, no. 2 (2023): 364–385.

[260] GBD 2016 neurology collaborators. “Global, Regional, and National Burden of Neurological Disorders, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016,” Lancet Neurology 18, no.5 (2019): 459–480.

[261] C. Ding, Y. Wu, X. Chen, et al., “Global, Regional, and National Burden and Attributable Risk Factors of Neurological Disorders: The Global Burden of Disease Study 1990–2019,” Frontiers in Public Health 10 (2022): 952161.

[262] S. Shaikh, L. Siddique, H. T. Khalifey, et al., “Brain Organoid Model Systems of Neurodegenerative Diseases: Recent Progress and Future Prospects,” Frontiers in Neuroscience 19 (2025): 1604435.

[263] O. L. Eichmüller and J. A. Knoblich, “Human Cerebral Organoids—a New Tool for Clinical Neurology Research,” Nature Reviews Nephrology 18, no. 11 (2022): 661–680.

[264] Y. Pomeshchik, O. Klementieva, J. Gil, et al., “Human iPSC-derived Hippocampal Spheroids: An Innovative Tool for Stratifying Alzheimer Disease Patient-specific Cellular Phenotypes and Developing Therapies,” Stem Cell Reports 15, no. 1 (2020): 256–273.

[265] S. A. Small, S. A. Schobel, R. B. Buxton, et al., “A Pathophysiological Framework of Hippocampal Dysfunction in Ageing and Disease,” Nature Reviews Neuroscience 12, no. 10 (2011): 585–601.

[266] Y. Wu, J. Cheng, J. Qi, et al., “Three-dimensional Liquid Metal-based Neuro-interfaces for human Hippocampal Organoids,” Nature Communications 15, no. 1 (2024): 4047.

[267] W. Poewe, K. Seppi, C. M. Tanner, et al., “Parkinson Disease,” Nature Reviews Disease Primers 3 (2017): 17013.

[268] F. Stocchi, D. Bravi, A. Emmi, et al., “Parkinson Disease Therapy: Current Strategies and Future Research Priorities,” Nature Reviews Nephrology 20, no. 12 (2024): 695–707.

[269] X. Cui, X. Li, H. Zheng, et al., “Human Midbrain Organoids: A Powerful Tool for Advanced Parkinson's Disease Modeling and Therapy Exploration,” NPJ Parkinsons Disease 10, no. 1 (2024): 189.

[270] A. Fiorenzano, E. Sozzi, R. Kastli, et al., “Advances, Challenges, and Opportunities of human Midbrain Organoids for Modelling of the Dopaminergic System,” EMBO Journal 44, no. 15 (2025): 4181–4195.

[271] H. Kim, H. J. Park, H. Choi, et al., “Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids,” Stem Cell Reports 12, no. 3 (2019): 518–531.

[272] A. S. Monzel, L. M. Smits, K. Hemmer, et al., “Derivation of human Midbrain-specific Organoids From Neuroepithelial Stem Cells,” Stem Cell Reports 8, no. 5 (2017): 1144–1154.

[273] G. Morrone Parfitt, E. Coccia, C. Goldman, et al., “Disruption of Lysosomal Proteolysis in Astrocytes Facilitates Midbrain Organoid Proteostasis Failure in an Early-onset Parkinson's Disease Model,” Nature Communications 15, no. 1 (2024): 447.

[274] H. Gao, Y. Zeng, X. Huang, et al., “Extracellular Vesicles From Organoid-derived human Retinal Progenitor Cells Prevent Lipid Overload-induced Retinal Pigment Epithelium Injury by Regulating Fatty Acid Metabolism,” Journal of Extracellular Vesicles 13, no. 1 (2024): e12401.

[275] P. Wahle, G. Brancati, C. Harmel, et al., “Multimodal Spatiotemporal Phenotyping of human Retinal Organoid Development,” Nature Biotechnology 41, no. 12 (2023): 1765–1775.

[276] M. Kloppenburg, M. Namane, and F. Cicuttini, “Osteoarthritis,” Lancet 405, no. 10472 (2025): 71–85.

[277] J. D. Steinmetz, G. T. Culbreth, L. M. Haile, et al., “Global, Regional, and National Burden of Osteoarthritis, 1990–2020 and Projections to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021,” Lancet Rheumatology 5, no. 9 (2023): E508–E522.

[278] X. Li, S. Sheng, G. Li, et al., “Research Progress in Hydrogels for Cartilage Organoids,” Advanced Healthcare Materials 13, no. 22 (2024): e2400431.

[279] C. Shen, Z. Zhou, R. Li, et al., “Silk Fibroin-based Hydrogels for Cartilage Organoids in Osteoarthritis Treatment,” Theranostics 15, no. 2 (2025): 560–584.

[280] Y. Yoshimura, Y. Muto, N. Ledru, et al., “A Single-cell Multiomic Analysis of Kidney Organoid Differentiation,” Proceedings of the National Academy of Sciences of the United States of America 120, no. 20 (2023): e2219699120.

[281] M. A. Mall, P. R. Burgel, C. Castellani, et al., “Cystic Fibrosis,” Nature Reviews Disease Primers 10, no. 1 (2024): 53.

[282] H. Grasemann and F. Ratjen, “Cystic Fibrosis,” New England Journal of Medicine 389, no. 18 (2023): 1693–1707.

[283] M. Shteinberg, I. J. Haq, D. Polineni, et al., “Cystic Fibrosis,” Lancet 397, no. 10290 (2021): 2195–2211.

[284] M. P. Dumas, S. Xia, C. E. Bear, et al., “Perspectives on the Translation of in-vitro Studies to Precision Medicine in Cystic Fibrosis,” EBioMedicine 73 (2021): 103660.

[285] E. de Poel, J. W. Lefferts, and J. M. Beekman, “Intestinal Organoids for Cystic Fibrosis Research,” Journal of Cystic Fibrosis 19, no. Suppl 1 (2020): S60–s64.

[286] J. F. Dekkers, G. Berkers, E. Kruisselbrink, et al., “Characterizing Responses to Cftr-modulating Drugs Using Rectal Organoids Derived From Subjects With Cystic Fibrosis,” Science Translational Medicine 8, no. 344 (2016): 344ra384.

[287] P. Strnad, N. G. McElvaney, and D. A. Lomas, “Alpha1-antitrypsin Deficiency,” New England Journal of Medicine 382, no. 15 (2020): 1443–1455.

[288] A. Czlonkowska, T. Litwin, P. Dusek, et al., “Wilson Disease,” Nature Reviews Disease Primers 4, no. 1 (2018): 21.

[289] Q. Lin, Y. Zong, C. Xue, et al., “Prime Genome Editing in Rice and Wheat,” Nature Biotechnology 38, no. 5 (2020): 582–585.

[290] C. Bergmann, L. M. Guay-Woodford, P. C. Harris, et al., “Polycystic Kidney Disease,” Nature Reviews Disease Primers 4, no. 1 (2018): 50.

[291] E. Cornec-Le Gall, A. Alam, and R. D. Perrone, “Autosomal Dominant Polycystic Kidney Disease,” Lancet 393, no. 10174 (2019): 919–935.

[292] E. Cornec-Le Gall, V. E. Torres, and P. C. Harris, “Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases,” Journal of the American Society of Nephrology 29, no. 1 (2018): 13–23.

[293] N. M. Cruz, X. Song, S. M. Czerniecki, et al., “Organoid Cystogenesis Reveals a Critical Role of Microenvironment in human Polycystic Kidney Disease,” Nature Materials 16, no. 11 (2017): 1112–1119.

[294] K. Hiratsuka, T. Miyoshi, K. T. Kroll, et al., “Organoid-on-a-chip Model of human ARPKD Reveals Mechanosensing Pathomechanisms for Drug Discovery,” Science Advances 8, no. 38 (2022): eabq0866.

[295] C. Zhou, Y. Wu, Z. Wang, et al., “Standardization of Organoid Culture in Cancer Research,” Cancer Medicine 12, no. 13 (2023): 14375–14386.

[296] E. Garreta, P. Prado, C. Tarantino, et al., “Fine Tuning the Extracellular Environment Accelerates the Derivation of Kidney Organoids From human Pluripotent Stem Cells,” Nature Materials 18, no. 4 (2019): 397–405.

[297] S. Kaur, I. Kaur, P. Rawal, et al., “Non-matrigel Scaffolds for Organoid Cultures,” Cancer Letters 504 (2021): 58–66.

[298] M. Czerwinski and J. R. Spence, “Hacking the Matrix,” Cell Stem Cell 20, no. 1 (2017): 9–10.

[299] X. Lyu, J. Wang, and J. Su, “Intelligent Manufacturing for Osteoarthritis Organoids,” Cell Proliferation 58, no. 7 (2025): e70043.

[300] H. Liu, T. Tao, Z. Gan, et al., “Organoid in Droplet: Production of Uniform Pancreatic Cancer Organoids From Single Cells,” Materials Today Bio 32 (2025): 101765.

[301] H. T. Nguyen, E. L. Kan, M. Humayun, et al., “Patient-specific Vascularized Tumor Model: Blocking Monocyte Recruitment With Multispecific Antibodies Targeting CCR2 and CSF-1R,” Biomaterials 312 (2025): 122731.

[302] K. A. Homan, N. Gupta, K. T. Kroll, et al., “Flow-enhanced Vascularization and Maturation of Kidney Organoids in Vitro,” Nature Methods 16, no. 3 (2019): 255–262.

[303] M. A. Skylar-Scott, J. Y. Huang, A. Lu, et al., “Orthogonally Induced Differentiation of Stem Cells for the Programmatic Patterning of Vascularized Organoids and Bioprinted Tissues,” Nature Biomedical Engineering 6, no. 4 (2022): 449–462.

[304] C. M. Cattaneo, K. K. Dijkstra, L. F. Fanchi, et al., “Tumor Organoid-T-cell Coculture Systems,” Nature Protocols 15, no. 1 (2020): 15–39.

[305] N. F. Shroyer, “Tumor Organoids Fill the Niche,” Cell Stem Cell 18, no. 6 (2016): 686–687.

[306] Z. J. Li, D. Y. Yu, C. Y. Zhou, et al., “Engineering Vascularised Organoid-on-a-chip: Strategies, Advances and Future Perspectives,” Biomaterials Translational 5, no. 1 (2024): 21–32.

[307] W. R. Ye, C. Luo, C. L. Li, et al., “Organoids to Study Immune Functions, Immunological Diseases and Immunotherapy,” Cancer Letters 477 (2020): 31–40.

[308] C. Li, J. S. Fleck, C. Martins-Costa, et al., “Single-cell Brain Organoid Screening Identifies Developmental Defects in Autism,” Nature 621, no. 7978 (2023): 373–380.

[309] H. Xu, D. Jiao, A. Liu, et al., “Tumor Organoids: Applications in Cancer Modeling and Potentials in Precision Medicine,” Journal of Hematology & Oncology 15, no. 1 (2022): 58.

[310] S. N. Boers and A. L. Bredenoord, “Consent for Governance in the Ethical Use of Organoids,” Nature Cell Biology 20, no. 6 (2018): 642–645.

[311] J. Wang, X. Chen, R. Y. Li, et al., “Standardization and Consensus in the Development and Application of Bone Organoids,” Theranostics 15, no. 2 (2025): 682–706.

[312] M. De Palma and D. Hanahan, “Milestones in Tumor Vascularization and Its Therapeutic Targeting,” Nature Cancer 5, no. 6 (2024): 827–843.

[313] Q. Gao, J. Wang, H. Zhang, et al., “Organoid Vascularization: Strategies and Applications,” Advanced Healthcare Materials 14, no. 20 (2025): e2500301.

[314] Y. Miao, N. M. Pek, C. Tan, et al., “Co-development of Mesoderm and Endoderm Enables Organotypic Vascularization in Lung and Gut Organoids,” Cell 188, no. 16 (2025): 4295–4313.

[315] N. Saiki, Y. Nio, Y. Yoneyama, et al., “Self-organization of Sinusoidal Vessels in Pluripotent Stem Cell-derived human Liver Bud Organoids,” Nature Biomedical Engineering 9, no. 11 (2025): 1869–1885.

[316] O. J. Abilez, H. Yang, Y. Guan, et al., “Gastruloids Enable Modeling of the Earliest Stages of human Cardiac and Hepatic Vascularization,” Science 388, no. 6751 (2025): eadu9375.

[317] S. Kanton and S. P. Paşca, “Human Assembloids,” Development (Cambridge, England) 149, no. 20 (2022): dev201120.

[318] N. Vogt, “Assembloids,” Nature Methods 18, no. 1 (2021): 27.

[319] M. M. Onesto, J. I. Kim, and S. P. Pasca, “Assembloid Models of Cell-cell Interaction to Study Tissue and Disease Biology,” Cell Stem Cell 31, no. 11 (2024): 1563–1573.

[320] L. Bai, J. Li, G. Li, et al., “Skeletal Interoception and Prospective Application in Biomaterials for Bone Regeneration,” Bone Research 13, no. 1 (2025): 1.

[321] S. P. Paşca, “Assembling human Brain Organoids,” Science 363, no. 6423 (2019): 126–127.

[322] M. M. Onesto, N. D. Amin, C. Pan, et al., “Midline Assembloids Reveal Regulators of human Axon Guidance,” Science 389, no. 6757 (2025): 282–289.

[323] G. Gomez-Giro, D. Frangenberg, D. Vega, et al., “Α-synuclein Pathology Spreads in a Midbrain-hindbrain Assembloid Model,” Advanced Science (Weinh) 12, no. 20 (2025): e2409040.

[324] F. X. Wang, P. R. Song, J. Wang, et al., “Organoid Bioinks: Construction and Application,” Biofabrication 16, no. 3 (2024): 032006.

[325] S. Maharjan, C. Ma, B. Singh, et al., “Advanced 3D Imaging and Organoid Bioprinting for Biomedical Research and Therapeutic Applications,” Advanced Drug Delivery Reviews 208 (2024): 115237.

[326] Y. Zhang, G. Li, J. Wang, et al., “Small Joint Organoids 3D Bioprinting: Construction Strategy and Application,” Small 20, no. 8 (2024): e2302506.

[327] J. A. Brassard, M. Nikolaev, T. Hübscher, et al., “Recapitulating Macro-scale Tissue Self-organization Through Organoid Bioprinting,” Nature Materials 20, no. 1 (2021): 22–29.

[328] J. Rouwkema and A. Khademhosseini, “Vascularization and Angiogenesis in Tissue Engineering: Beyond Creating Static Networks,” Trends in Biotechnology 34, no. 9 (2016): 733–745.

[329] K. T. Lawlor, J. M. Vanslambrouck, J. W. Higgins, et al., “Cellular Extrusion Bioprinting Improves Kidney Organoid Reproducibility and Conformation,” Nature Materials 20, no. 2 (2021): 260–271.

[330] X. X. Ren, J. Wang, Y. Wu, et al., “One-pot Synthesis of Hydroxyapatite Hybrid Bioinks for Digital Light Processing 3D Printing in Bone Regeneration,” Journal of Materials Science & Technology 188 (2024): 84–97.

[331] H. Shi, A. Kowalczewski, D. Vu, et al., “Organoid Intelligence: Integration of Organoid Technology and Artificial Intelligence in the New Era of in Vitro Models,” Medicines in Novel Technology and Devices 21 (2024): 100276.

[332] L. Bai, Y. Wu, G. Li, et al., “Ai-enabled Organoids: Construction, Analysis, and Application,” Bioactive Materials 31 (2024): 525–548.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.